title: Loss of heterozygosity and immunohistochemistry of adenocarcinomas of the esophagus and gastric cardia.
abstract: OBJECTIVE
  Adenocarcinomas of the distal esophagus and gastric cardia are two tumors that have many features in common. They have similar prognoses, treatment modalities, and patterns of dissemination. The etiology is different, with gastroesophageal reflux disease playing a major role for esophageal adenocarcinoma, in contrast to adenocarcinoma of the gastric cardia. In the present study, we investigated several genetic and immunohistochemical features of adenocarcinomas of the distal esophagus and gastric cardia.
  
  
  METHODS
  Sixty-two resection specimens of either adenocarcinoma of the esophagus or adenocarcinoma of the gastric cardia were carefully selected. The genetic analysis included loss of heterozygosity of several tumor suppressor genes known to be involved in esophagogastric carcinogenesis. Immunohistochemical studies included the analysis of p53, c-Met, c-erbB-2, beta-catenin, and cyclooxygenase-2. In addition, a mutation analysis of the Tcf1 gene was done by direct sequencing.
  
  
  RESULTS
  Patients with cardiac carcinoma had a significantly worse tumor stage and poorer differentiation on histology. Loss of heterozygosity analysis did not reveal significant differences between esophageal adenocarcinoma and cardiac adenocarcinoma. Immunohistochemical analysis revealed significantly more nuclear accumulation of beta-catenin and overexpression of cyclooxygenase-2 in patients with esophageal adenocarcinoma, compared with patients with cardiac carcinoma. No mutation was found in the Tcf1 gene in either tumor type.
  
  
  CONCLUSIONS
  Although adenocarcinomas of the distal esophagus and gastric cardia have many features in common, we have found some evidence that they might form two different entities.
authors.affiliation: Department of Experimental Hepatology, Academic Medical Center, Amsterdam, The Netherlands. w.a.marsman@amc.uva.nl
authors.forename: Willem A
authors.initials: WA
authors.lastname: Marsman
authors.forename: Rakesh S
authors.initials: RS
authors.lastname: Birjmohun
authors.forename: Bastiaan P
authors.initials: BP
authors.lastname: van Rees
authors.forename: Eric
authors.initials: E
authors.lastname: Caspers
authors.forename: G
authors.initials: G
authors.lastname: Johan
authors.forename: A
authors.initials: A
authors.lastname: Offerhaus
authors.forename: Piter J
authors.initials: PJ
authors.lastname: Bosma
authors.forename: J
authors.initials: J
authors.lastname: Jan
authors.forename: B
authors.initials: B
authors.lastname: van Lanschot
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000368:Aged; D002299:Cardia / Q000473:pathology*; D004273:DNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D005260:Female; D016147:Genes, Tumor Suppressor / Q000502:physiology*; D006801:Humans; D007124:Immunoenzyme Techniques; D019656:Loss of Heterozygosity; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D013274:Stomach Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology
chemical_list: D004273:DNA, Neoplasm